Imagine a heart bypass as a detour road for blood. Instead of taking a vein from the patient's leg to build this detour, which causes pain and complications, this technology uses a smart synthetic tube. This tube acts like a scaffold that encourages the body to grow its own natural tissue inside it, eventually replacing the synthetic material with a living vessel.
Traditional heart bypass surgery requires harvesting veins from the legs, causing chronic pain and complications. Furthermore, over 20% of these grafts fail within one year.
The XABG and XABG-XS restorative vascular grafts, which are synthetic scaffolds that allow the body to regrow natural heart tissue.
If you are a manufacturer dealing with the high failure rate of traditional grafts where >20% occlude after 1 year — this project developed the XABG restorative graft that allows the body to naturally restore vascular tissue. This reduces the need for risky vein harvesting from legs.
If you are a hospital dealing with costly complications and chronic pain from leg vein harvesting — this project developed a synthetic graft that eliminates the need for this procedure. This improves patient recovery times and reduces post-operative complications.
If you are a pharma company dealing with the need for precise post-op medication regimens — this project identified that intensified Dual Anti-Platelet Therapy (DAPT) for at least 12 months is critical for graft patency. This creates a specific clinical pathway for anticoagulant drug administration.
Based on available project data, the specific unit cost or market price of the graft is not mentioned.
The project aims to perform full clinical validation to obtain a CE mark in Europe, which will then trigger market deployment and commercial up-scaling.
Based on available project data, specific patent numbers or licensing terms are not provided, though the technology is developed by Xeltis BV.
The project is focused on obtaining the CE mark in Europe through full clinical validation.
The project period runs from 2022-12-01 to 2025-11-30, with the goal of achieving CE marking by the end of this period.
The consortium is highly streamlined and industry-focused, consisting of 2 SMEs from the Netherlands and Switzerland. With a 100% industry ratio, the project is designed for rapid commercialization rather than academic research, leveraging the agility of small-to-medium enterprises to move from clinical trials to CE marking.
Contact XELTIS BV in the Netherlands for licensing and clinical partnership inquiries.
Contact us to find similar bioabsorbable medical device innovations for your portfolio.
